A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

This study is testing a combination of two targeted drugs — venetoclax and revumenib — in patients with a type of blood cancer called acute myeloid leukemia (AML) who are in remission but still have small amounts of cancer cells detectable in their bone marrow (called measurable residual disease, or MRD). **You may be eligible if...** - You are 12 years or older (and weigh at least 45 kg) - You have a history of AML with specific gene mutations (NPM1, KMT2A, or NUP98 rearrangements) - Your bone marrow shows remission (less than 5% cancer cells) but lab tests still detect low levels of cancer - Your heart and organ function meet minimum health requirements **You may NOT be eligible if...** - Your cancer is no longer in remission or has spread outside the bone marrow - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.